Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Principal TechnologiesFRA:JO7 -18.75%12 Net Current Asset Value is €-0.02 as of Apr. 2026. GuruFocus rates FRA:JO7 with a GF Score™ of 12/100 and a GF Value™ of €0.04 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 273 Healthcare Providers & Services companies, Principal Technologies ranks worse than 366300% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Principal Technologies's net current asset value per share for the quarter that ended in Apr. 2026 was €-0.02.
The historical rank and industry rank for Principal Technologies's Net Current Asset Value or its related term are showing as below:
During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Principal Technologies was 20.00. The lowest was 2.50. And the median was 15.00.
FRA:JO7's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Principal Technologies (FRA:JO7) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Principal Technologies Net Current Asset Value Related Terms
Principal Technologies Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Principal Technologies's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Principal Technologies Net Current Asset Value Chart
FRA:JO7 vs VEEV, BTSG, TEM: Net Current Asset Value Comparison
For the Health Information Services subindustry, Principal Technologies's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Principal Technologies Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Principal Technologies's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-0.02 mean?
Principal Technologies (FRA:JO7) has a Net Current Asset Value of €-0.02 as of Apr. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Principal Technologies and its competitors. Over the past decade, Principal Technologies' Net Current Asset Value has ranged from 2.50 to 20.00. According to the industry distribution chart, Principal Technologies ranks #999999 out of 273 companies in the Healthcare Providers & Services industry.
Is Principal Technologies' Net Current Asset Value too high?
Principal Technologies' current Net Current Asset Value is €-0.02. Over the past 10 years, this metric has ranged from a low of 2.50 to a high of 20.00. Based on the distribution chart, Principal Technologies ranks #999999 out of 273 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Principal Technologies has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Principal Technologies' Net Current Asset Value compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Principal Technologies ranks #999999 out of 273 companies for Net Current Asset Value. This places Principal Technologies in the lower half of its industry. The industry median Net Current Asset Value is 6.00. Historically, Principal Technologies' own Net Current Asset Value has ranged from 2.50 to 20.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 6.00, based on 273 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Principal Technologies and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Principal Technologies's current Net Current Asset Value is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Principal Technologies stock overvalued right now?
Based on GuruFocus' analysis, Principal Technologies (FRA:JO7) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.20 — trading 387.5% above its estimated fair value. The current Net Current Asset Value is €-0.02. Principal Technologies' overall GF Score™ is 12/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Principal Technologies (FRA:JO7), the current Net Current Asset Value is €-0.02 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Principal Technologies (FRA:JO7) Overvalued in 2026?
Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued.
The current stock price of €0.20 is trading 387.5% above its estimated GF Value™ of €0.04.
GuruFocus considers Principal Technologies to be Significantly Overvalued.
Key valuation signals for FRA:JO7:
Net Current Asset Value: €-0.02
GF Value™: €0.04 vs. price of €0.20 (387.5% above fair value)
No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
12GF Score
Get the complete analysis for FRA:JO7
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JO7 has been successfully added to your 
